New drug combo for rare bone marrow cancer shows early promise, but trial halted

NCT ID NCT06245941

Terminated Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrolled 21 adults and was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQ05105 and TQB3909 tablets
What this could lead to: If successful, this combination could offer a new treatment option for people with moderate- to high-risk myelofibrosis, potentially reducing spleen size and improving symptoms.
What could go wrong: The trial was terminated early, so results are limited. It was a small, early-phase study, so even if data are positive, much more testing is needed. The drugs may cause side effects like low blood counts or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

Hennan Cancer Hospital

Zhengzhou, Henan, 450003, China
People's Hospital of Tianjin

Tianjin, Tianjin Municipality, 300122, China
The First Affiliated Hospital Zhejiang University School Of Medicine

Hangzhou, Zhejiang, 310003, China
The Second People's Hospital of Hefei

Hefei, Anhui, 230012, China
Xijing Hospital of the Fourth Military Medical University

Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.